higher percentage of atrial fibrillation and chronic obstructive pulmonary disease in AID patients. Compared to non-AID patients, AID patients had similar clinical ACS presentation and no differences were found with respect to revascularization strategies or medical treatment at discharge. With respect to prognosis the two groups had comparable rates of adverse events during hospitalization (10% vs 10%, p=0.920) with no statistically significant differences in any single event studied. However after a follow-up of 397 years, AID patients had higher rate of combined adverse events (44% vs 28% p<0,001). After multivariate adjustment the presence of AID was associated with increased total mortality (hazard ratio 2.1, 95% CI 1.2 to 3.7, p=0.008) and it was also a borderline risk factor for higher bleeding complications (hazard ratio 2.2, 95% CI 0.9 to 5.5). The presence of AID was not an independent risk factor for neither stroke or recurrent non-fatal myocardial infarction.
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Conclusions:
The presence of AID did not change ACS presentation and clinical management. Although AID is not associated with worse outcomes during hospitalization it is independently linked to higher total mortality and a trend to an increased risk of major bleeding during follow-up. Methods: Study population: All subjects from one out of three centers who participated in a randomized clinical trial comparing high (3750 IU/day) versus low (600 IU/day) dose of vitamin D supplementation in ambulatory overweight (BMI exceeding 25) elderly subjects (age ≥65 years), with serum 25OHD level between 10 and 30 ng/ml at screening. Outcome measure: 25OH D serum levels at 12 months of follow-up. Confounders included gender, body mass index, baseline 25OHD serum level, genetic polymorphism of vitamin D receptor (Fok, BsmI and Taq) and dietary intake of vitamin D, calcium, proteins, carbohydrates, fats and total calories assessed by food frequency and 24h recall questionnaires, administered a year after the termination of the trial. Statistical analysis: ANOVA for repeated measures and regression using STATA version 13. Numbers expressed as mean (SD). Results: We studied 117 Participants, 62 females and 55 males, age was 71 (5) years, of who 61 received 3,750 IU of vitamin D, and 55 received 600 IU/day. Vitamin D receptor genetic polymorphisms distribution was comparable in both arms. Daily vitamin D intake excluding provided supplements was 7.59 (1.21) mcg and 8.53 (1.36) mcg from the 24 h recall, and food frequency questionnaires, respectively (p was NS between the two arms). Calories, calcium, protein, carbohydrate and fat mean intake was also similar across both arms. The high-dose group achieved significantly higher 25OH-vitamin D serum levels at twelve months 34.9 (9.3) ng/ml compared to low-dose, 21.9 (6.1) ng/ml (p<0.0001). Difference between arms remained significant adjusting for gender, baseline BMI, Fok, Bsml and Taq genetic polymorphism, baseline serum vitamin D and dietary intake of vitamin D, calcium, calories, proteins, carbohydrates and fats. None of these dietary intake measures was found to have significant contribution to the model variance. Supplementation dose was the only significant predictor of 25OHvitamin D serum levels achieved at 12 months. Conclusions: Diet composition was not a confounder for the effect of high versus low dose vitamin D 12-month supplementation, on achieved 25OHD vitamin D serum levels. Objectives: To characterize the main features at presentation of sarcoidosis associated with the development of end-stage organ failure in a large multicenter cohort of patients from Southern Europe. Methods: In January 2017, the Spanish National Registry of Sarcoidosis (SARCOGEAS-SEMI) included 1082 consecutive patients diagnosed with sarcoidosis according to the ATS/ERS/WASOG 1999 statement and extrathoracic involvement to the 2014 WASOG instrument. The development of end-stage organ failure was assessed at the last visit. Results: The cohort consisted of 618 (57%) women and 464 (43%) men, with a mean age at diagnosis of 47yrs. After a mean follow-up of 82 months, 90 (8%) patients developed end-stage organ failure, including respiratory failure (n=56), chronic renal failure (n=13), cardiac failure/permanent cardiac device (n=8) and liver cirrhosis (n=3). The following baseline features were associated with end-stage organ failure in the univariate analysis: patients born in Spain (p=0.008), a higher mean age at diagnosis (p<0.001) and a radiological stage III/IV (p<0.001) With respect to extrathoracic involvement, spleen (p=0.015), renal (p=0.001), cardiac (p=0.028) and bone marrow (p=0.003) involvements, hypercalcemia (p=0.018) and use of corticosteroids (p<0.001) were associated with end-stage organ failure, while patients with cutaneous sarcoidosis had a lower risk (p=0.029). Multivariate analysis identified age at diagnosis (OR 1.05), radiological stages III/IV (OR 3.12) and use of corticosteroids (OR 4.55) as independent variables associated with the development of end-stage organ failure. Conclusions: Nearly 10% of patients with sarcoidosis developed end-stage organ failure. Respiratory failure represented two thirds of cases of sarcoidosis-related organ failure, followed by renal (15% of cases) and cardiac (9%). Older patients, as well as those presenting with advanced radiological stages, had an enhanced risk of developing end-stage organ failure. Background: More than 80% of cases of tuberculosis are the result of reactivated latent infection, and nearly all these cases could be prevented by the administration of a course of antibiotic treatment. Therefore, it is suggested screening and treatment are most beneficial for those patients taking immunosuppressive medications. Although the prevalence of latent tuberculosis infection in China was much higher than the United States on the basis of tuberculin skin testing, In China, so far, no study has been done about prophylactic treatment on prevention of tuberculosis activation during glucocorticoid therapy in patients with rheumatic diseases. Should it been recommended that all patients with rheumatic diseases be screened for the presence of active tuberculosis or LTBI before the use of long term glucocorticoid or immunosuppressive medications in China? It is reported only about 5% of immunocompetent persons with a positive test will have progression from latent infection to disease in their lifetime. and decisions about whether to treat latent tuberculosis should take into account the individual patient's risk for the development of active tuberculosis and the risks of therapy. Objectives: To evaluate the risk of reactivation of LTBI in patients with rheumatic diseases who were undergoing prednisone use and the efficacy and safety of prophylactic treatment on prevention of tuberculosis reactivation. Methods: 1000 patients with rheumatic diseases who were treated with prednisone were enrolled since 2012. IGRA test (the T-SPOT.TB test) were performed for all subjects. 50 patients with a IGRA-positive were administrated with rifampin for 4 months. 2-years follow-up was conducted to evaluate the risk factors of reactivation of LTBI and the efficacy and safety of rifampin treatment on prevention of tuberculosis reactivation.
